Lisata Therapeutics Earnings Call Transcripts
Fiscal Year 2025
-
Q3 2025 saw reduced expenses and net loss, with $19M in cash projected to last into Q1 2027. Certepetide advanced across multiple cancer trials, showing positive efficacy and safety signals, while new partnerships and a key patent strengthened the pipeline.
-
A novel peptide adjuvant is showing significant survival and response improvements in solid tumor cancers, especially metastatic pancreatic cancer, with broad compatibility and no added toxicity. Multiple strategic partnerships, regulatory designations, and a strong financial position support ongoing and future clinical milestones.
-
Q2 2025 saw reduced expenses and a narrowed net loss, with $22M in cash supporting operations into Q4 2026. Multiple clinical milestones were achieved, including positive preliminary data for Certepetide and new strategic partnerships, while a key patent extended exclusivity to 2040.
-
Q1 2025 saw reduced expenses and net loss, with $25.8M in cash supporting operations into Q3 2026. Certepetide clinical programs advanced, with key trial data and milestones expected in the next 12–18 months. Multiple collaborations and licensing deals expand pipeline reach.
Fiscal Year 2024
-
Advanced clinical programs for certepetide in solid tumors showed positive early data, with 2024 financials reflecting reduced expenses and a strong cash position. Multiple key trial readouts and milestones are expected in 2025, supporting further development and potential partnerships.
-
Sirtepotide development advanced in multiple cancer types and endometriosis, with key clinical milestones and data readouts expected in 2025. Operating expenses and net loss decreased year-over-year, and current capital is projected to fund operations into early 2026.
-
A novel peptide platform is advancing in late-stage clinical trials for solid tumors, showing improved survival and efficacy in both preclinical and clinical settings. Multiple regulatory designations, strategic partnerships, and a strong financial position support upcoming milestones through 2026.
-
Certepetide clinical development advanced with multiple global trials, regulatory designations, and strong financial management. Key data readouts are expected in late 2024 and 2025, with cash reserves projected to fund operations into early 2026.